Antengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022

SHANGHAI and HONG KONG, Sept. 20, 2026 /PRNewswire/ — Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or...